A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas
Latest Information Update: 05 Jun 2023
At a glance
- Drugs Onzigolide (Primary)
- Indications Pituitary adenoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Tiburio Therapeutics
Most Recent Events
- 08 Nov 2020 This trial has been completed in Poland according to European Clinical Trials Database record.
- 29 Oct 2020 This trial has been discontinued in the United Kingdom, according to European Clinical Trials Database record.
- 14 Oct 2020 This trial has been discontinued in Hungary (Global End Date: 28 Sep 2020), according to European Clinical Trials Database record.